BioArctic AB Registered b News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

14.03.19	BioArctic Announces Start of Phase 1 Study of ABBV-0805 for Parkinson's Disease (PR Newswire)
14.03.19	BioArctic Announces Start of Phase 1 Study of ABBV-0805 for Parkinson's Disease (PR Newswire)
14.02.19	BioArctic - Full Year Report January - December 2018 (PR Newswire)
14.02.19	BioArctic - Full Year Report January - December 2018 (PR Newswire)
13.02.19	BioArctic's Product Candidate SC0806 for Treatment of Patients With Complete Spinal Cord Injury is now in Phase 2 (PR Newswire)
13.02.19	BioArctic's Product Candidate SC0806 for Treatment of Patients With Complete Spinal Cord Injury is now in Phase 2 (PR Newswire)
11.02.19	BioArctic: U.S. Food and Drug Administration Approves Investigational New Drug Applicationfor ABBV-0805 (PR Newswire)
11.02.19	BioArctic: U.S. Food and Drug Administration Approves Investigational New Drug Applicationfor ABBV-0805 (PR Newswire)
04.02.19	BioArctic Announces That Eisai Will Initiate Phase 3 Confirmatory Study With BAN2401 in Early Alzheimer's Disease (PR Newswire)
04.02.19	BioArctic Announces That Eisai Will Initiate Phase 3 Confirmatory Study With BAN2401 in Early Alzheimer's Disease (PR Newswire)
14.12.18	BioArctic Outlicenses its Alpha-synuclein Antibody Portfolio for Parkinson's Disease to AbbVie After Receiving Clearance (PR Newswire)
14.12.18	BioArctic Outlicenses its Alpha-synuclein Antibody Portfolio for Parkinson's Disease to AbbVie After Receiving Clearance (PR Newswire)
12.11.18	BioArctic is Awarded Grant From EU's Horizon 2020 for Participation in Research Consortium for Better Diagnostic Tools and Biomarkers for Parkinson's (PR Newswire)
08.11.18	Interim Report January - September 2018 (PR Newswire)
08.11.18	Interim Report January - September 2018 (PR Newswire)
02.11.18	BioArctic's Partner AbbVie Exercises its Option to License the Alpha-synuclein Antibody Portfolio for Parkinson's Disease (PR Newswire)
02.11.18	BioArctic's Partner AbbVie Exercises its Option to License the Alpha-synuclein Antibody Portfolio for Parkinson's Disease (PR Newswire)
25.10.18	BioArctic Announces Additional BAN2401 Phase 2b Study Results in Early Alzheimer's Disease Presented by Eisai at the 2018 CTAD Conference (PR Newswire)
25.10.18	BioArctic Announces Additional BAN2401 Phase 2b Study Results in Early Alzheimer's Disease Presented by Eisai at the 2018 CTAD Conference (PR Newswire)
03.10.18	BioArctic Receives European Patent Protection for a Medical Device for Treatment of Patients with Complete Spinal Cord Injury (PR Newswire)
13.09.18	BioArctic SIgns a Research Agreement With Brain Biomarker Solutions in Gothenburg AB to Develop New Diagnostics for Alzheimer's Disease (PR Newswire)
13.09.18	BioArctic SIgns a Research Agreement With Brain Biomarker Solutions in Gothenburg AB to Develop New Diagnostics for Alzheimer's Disease (PR Newswire)
03.09.18	BioArctic Expands the Research Collaboration With Uppsala University Concerning Antibody-based Diagnostic Imaging of the Brain in Alzheimer Patients (PR Newswire)
03.09.18	BioArctic Expands the Research Collaboration With Uppsala University Concerning Antibody-based Diagnostic Imaging of the Brain in Alzheimer Patients (PR Newswire)
07.08.18	BioArctic Obtains Exclusive Rights to Develop Antibody Treatments for Alzheimer's Disease from a Research Project Jointly Owned with Eisai (PR Newswire)
07.08.18	BioArctic Obtains Exclusive Rights to Develop Antibody Treatments for Alzheimer's Disease from a Research Project Jointly Owned with Eisai (PR Newswire)
25.07.18	BioArctic Announces Detailed Results of the BAN2401 Phase 2b Study in Early Alzheimer's Disease Presented at AAIC 2018 (PR Newswire)
25.07.18	BioArctic Announces Detailed Results of the BAN2401 Phase 2b Study in Early Alzheimer's Disease Presented at AAIC 2018 (PR Newswire)
18.07.18	BioArctic: Late Breaking Phase 2b Study Results of BAN2401 in Alzheimer's Disease Will be Webcast Live From AAIC 2018 by Eisai (PR Newswire)
18.07.18	BioArctic: Late Breaking Phase 2b Study Results of BAN2401 in Alzheimer's Disease Will be Webcast Live From AAIC 2018 by Eisai (PR Newswire)
10.07.18	BioArctic Receives Regulatory Approval in Finland for a Clinical Study in Patients With Complete Spinal Cord Injury (PR Newswire)
10.07.18	BioArctic Receives Regulatory Approval in Finland for a Clinical Study in Patients With Complete Spinal Cord Injury (PR Newswire)
10.07.18	BioArctic Announces Acceptance of BAN2401 Phase 2b Results for Oral Presentation at the AAIC 2018 (PR Newswire)
10.07.18	BioArctic Announces Acceptance of BAN2401 Phase 2b Results for Oral Presentation at the AAIC 2018 (PR Newswire)
06.07.18	BioArctic Announces Positive Topline Results of BAN2401 Phase 2b at 18 Months in Early Alzheimer's Disease (PR Newswire)
06.07.18	BioArctic Announces Positive Topline Results of BAN2401 Phase 2b at 18 Months in Early Alzheimer's Disease (PR Newswire)
16.05.18	BioArctic Receives This Year's SwedenBIO Award (PR Newswire)
16.05.18	BioArctic Receives This Year's SwedenBIO Award (PR Newswire)
14.05.18	BioArctic Extends the Research Collaboration With Uppsala University Regarding New Antibody Technology (PR Newswire)
14.05.18	BioArctic Extends the Research Collaboration With Uppsala University Regarding New Antibody Technology (PR Newswire)
26.04.18	BioArctic - Interim Report January - March 2018 (PR Newswire)
26.04.18	BioArctic - Interim Report January - March 2018 (PR Newswire)
25.04.18	Inclusion Completed of Patients With Complete Spinal Cord Injury in the First Panel of BioArctic's Ongoing Study (PR Newswire)
25.04.18	Inclusion Completed of Patients With Complete Spinal Cord Injury in the First Panel of BioArctic's Ongoing Study (PR Newswire)
21.03.18	BioArctic Receives Regulatory Approval in Norway for a Clinical Study in Patients With Complete Spinal Cord Injury (PR Newswire)
21.03.18	BioArctic Receives Regulatory Approval in Norway for a Clinical Study in Patients With Complete Spinal Cord Injury (PR Newswire)
19.03.18	BioArctic Receives Patent Protection in Japan for a Medical Device for Treatment of Patients With Complete Spinal Cord Injury (PR Newswire)
19.03.18	BioArctic Receives Patent Protection in Japan for a Medical Device for Treatment of Patients With Complete Spinal Cord Injury (PR Newswire)
21.02.18	BioArctic Receives Regulatory Approval in Estonia for a Clinical Study in Patients With Complete Spinal Cord Injury (PR Newswire)
21.02.18	BioArctic Receives Regulatory Approval in Estonia for a Clinical Study in Patients With Complete Spinal Cord Injury (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	53.56	3.72 %	K V
Sonova Hldg	318.50	3.11 %	K V
Part Grp Hldg	1’381.00	2.30 %	K V
Alcon	80.90	1.81 %	K V
Lonza Grp	580.40	1.79 %	K V
Nestle	74.18	-0.75 %	K V
Geberit	500.80	-0.91 %	K V
Kuehne+Nagel Int	204.60	-1.06 %	K V
Swisscom	506.50	-1.65 %	K V
Logitech Intl	79.90	-1.75 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu BioArctic AB Registered Shs -B-

Aktien Top/Flop

Meistgelesene Nachrichten